Navigation Links
Cybrexa Therapeutics Appoints Vishwas Paralkar, Ph.D. as Chief Scientific Officer
Date:9/20/2017

Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has appointed Vishwas Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar will lead the development of Cybrexa’s tumor targeting technology. He will report to Cybrexa’s president and CEO, Per Hellsund.

“I was impressed with Cybrexa’s revolutionary technology and excellent leadership team,” Dr. Paralkar said. “The team has had multiple past successes and I am excited to bring this technology to market.”

Dr. Paralkar has more than 20 years of experience in drug development, and brings extensive drug discovery expertise and knowledge to the team. He joins Cybrexa from Karos, Inc., where he was recently the chief scientific officer. Prior to that, he held numerous senior level positions at Pfizer. Vishwas is a very experienced drug developer responsible for submitting 8 INDs (including both small and large molecules) and one drug approval.

Hellsund commented, “We are very pleased to have Vishwas join our team. We are confident that his leadership and breadth of drug development experience will enable us to move our technology from the research stage into the clinic.”

Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. This approach will both improve the efficacy while at the same time reduce toxicity of existing cancer drugs. The Company has made significant progress since it’s inception and now has several drug candidates that are being run through its in vitro and in vivo screening platform. The objective is to have at least one of it’s TSDs ready for a phase I clinical trial within two years.

About Cybrexa:

Cybrexa was founded by successful entrepreneurs Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine. Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.

For more information about Cybrexa, please call 860-717-2731 or visit us on the web at http://www.cybrexa.com

Read the full story at http://www.prweb.com/releases/2017/09/prweb14715217.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cybrexa Therapeutics Secures $6 Million in Series B Financing
2. Renova Therapeutics co-founder awarded highest research honor by the U.S. Department of Veterans Affairs
3. Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
4. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
5. United Therapeutics Corporation Reports Second Quarter 2017 Financial Results
6. Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies
7. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
8. United Therapeutics Announces $250 Million Share Repurchase Program
9. Arrowhead Publishers’ 11th Annual Pain and Migraine Therapeutics Summit Set to Take Place This Fall in San Diego, CA
10. Open Therapeutics and the Center for Advancing Innovation Form Partnership
11. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it ... biological network, a depiction of a system of linkages and connections so complex ... associate professor of computer science at Worcester Polytechnic Institute (WPI) and director of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):